期刊文献+

超高效液相色谱-串联质谱法测定大鼠血浆中替诺福韦的浓度 被引量:1

Determination of Tenofovir Concentration in Rats Plasma by UPLC-MS/MS
原文传递
导出
摘要 目的:建立大鼠血浆中替诺福韦浓度的测定方法。方法:采用超高效液相色谱-串联质谱法。取6只大鼠单次灌胃给予富马酸替诺福韦酯100mg.kg-1,检测给药45min后血浆中药物浓度,以恩替卡韦为内标,选用阳离子固相萃取柱除去血浆中的蛋白质。色谱柱为AcquitybenUPLC-C18,流动相为0.2%甲酸水溶液(含40mmo.lL-1醋酸铵)-乙腈=97:3,流速为0.25mL.min-1,柱温为40℃,电喷雾正离子(ESI+)源,监测离子对分别为质荷比(m/z)287.9→175.7(替诺福韦)和m/z277.9→151.7(恩替卡韦)。结果:替诺福韦检测浓度的线性范围为10~800ng.mL-1(r=0.9992),最低检测限为10ng.mL-1,回收率为(100.22±9.47)%~(102.76±4.99)%,日间、日内RSD均小于9.4%;给药45min后血浆样品中替诺福韦的平均浓度为819.2ng.mL-1。结论:该方法操作简便、专属性强、灵敏度高,可用于血浆中替诺福韦的浓度测定。 OBJECTIVE: To establish the method for the determination of tenofovir concentration in rat plasma. METHODS: UPLC-MS/MS was adopted. 6 rats were given single intragastric administration of tenofovir disoproxil fumarate 100 mg. kg-1. Drug concentration in plasma 45 min after administration was determined. Plasma protein was removed by cation solid phase extraction using entecavir as internal standard. The separation was performed on Acquity ben UPLC-C18 column with a mobile phase consisted of 0.2 % formic acid (containing 40 mmol. L-1 ammonium)-acetonitrile (97:3) at the flow rate of 0.25 mL. min-1. The column tem- perature was 40℃. Electrospray ionization source(ESF) was applied. The MS/MS detection was carded out by monitoring the fragmentation of m/z 287.9→175.7 for tenofovir and m/z 277.9→151.7 for entecavir. RESULTS: The linear range of tenofovir was 10- 800 ng.mL-1(r=0.999 2), and the lowest detection limit was 10 ng.mL-1. Relative recoveries were (100.22 ± 9.47)%-(102.76 ± 4.99) % ; RSD of intra-day and inter-day were both less than 9.4%. Average concentration of tenofovir in plasma sample 45 min after administration was 819.2 ng.mL-1.CONCLUSION: The method is simple, specific and sensitive, and suitable for the determination of tenofovir concentration in plasma.
出处 《中国药房》 CAS CSCD 2012年第13期1180-1182,共3页 China Pharmacy
关键词 替诺福韦 超高效液相色谱-串联质谱法 大鼠 浓度测定 Tenofovir UPLC-MS/MS Rats Concentration determination
  • 相关文献

参考文献7

  • 1Reynaud L,Carleo MA,Talamo M,et al.Tenofovir andits potential in the treatment of hepatitis B virus[J].Ther Clin Risk Manag,2009,5(3):177.
  • 2郭红英,张继明.替诺福韦酯治疗慢性乙型肝炎的研究进展[J].世界临床药物,2007,28(12):734-737. 被引量:7
  • 3张秋荣,王彩凤,可钰,郑甲信,刘宏民.抗人类免疫缺陷病毒药物的研究进展[J].中国药房,2010,21(5):460-461. 被引量:3
  • 4Grim SA,Romanelli F.Tenofovir disoproxil fumarate[J].Ann Pharmacother,2003,37(6):849.
  • 5Sentenac S,Fernandez C,Thuillier A,et al.Sensitive det-ermination of tenofovir in human plasma samples using re-versed-phase liquid chromatography[J].J Chromatogr B,2003,793(2):317.
  • 6El Barkil M,Gagnieu MC,Guitton J.Relevance of a co-mbined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring[J].J Chromatogr B Analyt Technol Biomed Life Sci,2007,854(1-2):192.
  • 7Guo J,Meng F,Li L,et al.Development and validation of an LC/MS/MS method for the determination of tenofovir in monkey plasma[J].Biol Pharm Bull,2011,34(6):877.

二级参考文献17

  • 1崔岚,安富荣,王晓珉.核苷酸逆转录酶抑制剂替诺福韦DF[J].中国新药杂志,2004,13(11):1054-1058. 被引量:30
  • 2毕毅,徐进宜,吴晓明.抗艾滋病药物的研究进展[J].中国现代应用药学,2005,22(6):461-465. 被引量:6
  • 3Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1[J].Antimicrob Agents Chemother, 2005, 49 (12):4911.
  • 4Harris M, Montaner JS. Clinical uses of non-nucleoside reverse transcriptase inhibitors[J].Rev Med Viro, 2000, 10 (4):217.
  • 5Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection[J].Drugs, 2003,63 (8) : 769.
  • 6Sorberal A, Serradell N, Ros A, et al. Rilpivirine: reverse transcriptase inhibitor: anti-HIV agent[J]. Drugs Future, 2007,32 ( 12 ) : 1 046.
  • 7De Clercq E, Field HJ. Antiviral Chemistry & Chem otherapy' s current amiviral agents FactFile (2nd edition) : retroviruses and hepadnaviruses[J].Antivir Chem Chemother, 2008,19 (2) : 75.
  • 8Aruksakunwong O, Promsis K, Wittayanarakul K, et al. Current development on HIV-1 protease inhibitors[J]. Curr Pharm Des, 2007,3 (3) : 201.
  • 9Ysunila R, Susanl F, Maggiet A, et al. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects[J].Antimicrob Agents Chemother , 2007, 51 (4) : 1 202.
  • 10Robert K, Mona P, Robert EW, et al.Synthesis, antiviral activity and pharmacokinetics of P1/P1' aubstituted 3- aminoindazole cyclic urea HIV protease inhibitors[J]. Bioorg Med Chem Lett , 2003,13 (6) : 605.

共引文献8

同被引文献9

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部